By otakuyassine3@gmail.com 
Vericel (NASDAQ:VCEL – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $60.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 2.27% from the stock’s current price.
A number of other brokerages also recently weighed in on VCEL. Truist Financial lifted their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Stephens raised Vericel to a “strong-buy” rating in a research note on Monday, December 2nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a report on Tuesday, November 19th. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. Finally, BTIG Research boosted their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $61.14.
Read Our Latest Research Report on Vericel
Vericel Stock Down 1.6 %
NASDAQ VCEL opened at $58.67 on Wednesday. The business’s fifty day moving average is $56.61 and its 200 day moving average is $49.84. Vericel has a twelve month low of $37.35 and a twelve month high of $61.49. The company has a market cap of $2.90 billion, a price-to-earnings ratio of 978.00 and a beta of 1.72.
Vericel (NASDAQ:VCEL – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $57.91 million during the quarter, compared to analysts’ expectations of $55.32 million. On average, research analysts anticipate that Vericel will post 0.13 earnings per share for the current fiscal year.
Insider Transactions at Vericel
In other news, insider Jonathan Mark Hopper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total value of $587,200.00. Following the transaction, the insider now owns 58,371 shares in the company, valued at $3,427,545.12. The trade was a 14.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total value of $150,000.00. Following the sale, the director now directly owns 26,595 shares of the company’s stock, valued at $1,595,700. The trade was a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,100 shares of company stock valued at $889,872 over the last ninety days. 5.20% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of VCEL. Geneva Capital Management LLC boosted its holdings in shares of Vericel by 61.4% in the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock worth $46,660,000 after buying an additional 420,078 shares during the last quarter. Wellington Management Group LLP raised its position in Vericel by 214.0% in the third quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock worth $24,837,000 after acquiring an additional 400,667 shares during the period. Congress Asset Management Co. boosted its stake in Vericel by 37.4% in the third quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company’s stock valued at $54,575,000 after acquiring an additional 351,550 shares during the last quarter. TimesSquare Capital Management LLC boosted its stake in Vericel by 54.8% in the third quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company’s stock valued at $24,934,000 after acquiring an additional 209,009 shares during the last quarter. Finally, Polar Asset Management Partners Inc. bought a new position in shares of Vericel during the 3rd quarter valued at approximately $4,973,000.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Featured Articles
Receive News & Ratings for Vericel Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vericel and related companies with MarketBeat.com’s FREE daily email newsletter.